IP Osgoode

Tag: Ruby Chapman

Novartis challenges Indian IP law

A Swiss pharmaceutical company, Novartis, sought to have the January 2006 decision to reject its patent application for the cancer drug imatinib mesylate (Gleevec) reversed

Read More »
Search
Categories
Newsletter
Skip to content